Myriad Genetics Launches Prolaris + AI Test for Personalized Prostate Cancer Active Surveillance

Why It Matters

By delivering both long‑term prognostic and immediate upgrade risk data, the test helps clinicians avoid overtreatment while ensuring high‑risk patients receive timely intervention, reshaping prostate‑cancer management.

Key Takeaways

• AI‑GUR predicts Gleason upgrades in 3+3/3+4 prostate cancers
• Prolaris + AI merges CCR score with AI risk model for surveillance
• Validation: 998 training, 296 validation patients showed independent prediction
• Launch May 29 2026 across US; New York approval pending
• Personalized monitoring may lower overtreatment and improve outcomes

Pulse Analysis

Prostate cancer remains the most common non‑skin malignancy among U.S. men, and active surveillance has become the standard for low‑risk disease. Yet clinicians often grapple with uncertainty about which patients might progress to higher‑grade tumors, leading to either unnecessary treatment or delayed intervention. Myriad Genetics, a leader in molecular diagnostics, has leveraged its Prolaris CCR assay—already trusted for long‑term prognosis—to incorporate a digital‑pathology AI model that evaluates tissue morphology for imminent Gleason score upgrades. This hybrid approach reflects a broader industry shift toward combining genomics with AI to refine risk stratification.

The AI‑GUR (Gleason Upgrade Risk) algorithm was trained on nearly a thousand biopsy specimens and independently validated on 296 cases, demonstrating statistically significant, independent prediction of Gleason upgrades at the first follow‑up biopsy for patients initially diagnosed with Gleason 3+3 or 3+4 disease. By extracting subtle patterns invisible to the human eye, the model adds a near‑term risk dimension that complements the Prolaris CCR’s long‑term survival outlook. This dual‑metric test equips urologists with actionable data to tailor surveillance intensity—potentially extending intervals for low‑risk patients while flagging those who may benefit from earlier therapeutic intervention.

The commercial rollout, slated for May 29, 2026 across the United States, positions Myriad at the forefront of precision oncology for prostate cancer. Payers are likely to view the test favorably if it demonstrably reduces unnecessary biopsies and treatments, translating into cost savings and improved quality of life. As regulatory clearance in New York is anticipated, broader adoption could accelerate the integration of AI‑enhanced diagnostics into standard care pathways, setting a precedent for similar genomics‑AI hybrids in other oncology indications.